207 related articles for article (PubMed ID: 23840792)
1. Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.
Fozzatti L; Park JW; Zhao L; Willingham MC; Cheng SY
PLoS One; 2013; 8(6):e67954. PubMed ID: 23840792
[TBL] [Abstract][Full Text] [Related]
2. Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1).
Fozzatti L; Lu C; Kim DW; Park JW; Astapova I; Gavrilova O; Willingham MC; Hollenberg AN; Cheng SY
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17462-7. PubMed ID: 21987803
[TBL] [Abstract][Full Text] [Related]
3. Genetic and Pharmacological Targeting of Transcriptional Repression in Resistance to Thyroid Hormone Alpha.
Freudenthal B; Shetty S; Butterfield NC; Logan JG; Han CR; Zhu X; Astapova I; Hollenberg AN; Cheng SY; Bassett JHD; Williams GR
Thyroid; 2019 May; 29(5):726-734. PubMed ID: 30760120
[No Abstract] [Full Text] [Related]
4. Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor α.
Fozzatti L; Kim DW; Park JW; Willingham MC; Hollenberg AN; Cheng SY
Proc Natl Acad Sci U S A; 2013 May; 110(19):7850-5. PubMed ID: 23610395
[TBL] [Abstract][Full Text] [Related]
5. NCOR1 modulates erythroid disorders caused by mutations of thyroid hormone receptor α1.
Han CR; Park S; Cheng SY
Sci Rep; 2017 Dec; 7(1):18080. PubMed ID: 29273766
[TBL] [Abstract][Full Text] [Related]
6. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.
Lu C; Zhu X; Willingham MC; Cheng SY
Oncogene; 2012 Apr; 31(16):2007-16. PubMed ID: 21909131
[TBL] [Abstract][Full Text] [Related]
7. NCoR1-independent mechanism plays a role in the action of the unliganded thyroid hormone receptor.
Mendoza A; Astapova I; Shimizu H; Gallop MR; Al-Sowaimel L; MacGowan SMD; Bergmann T; Berg AH; Tenen DE; Jacobs C; Lyubetskaya A; Tsai L; Hollenberg AN
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):E8458-E8467. PubMed ID: 28923959
[TBL] [Abstract][Full Text] [Related]
8. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
9. Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model.
Kim WG; Park JW; Willingham MC; Cheng SY
Endocrinology; 2013 Aug; 154(8):2936-47. PubMed ID: 23748362
[TBL] [Abstract][Full Text] [Related]
10. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
11. Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor.
Zhao L; Zhu X; Won Park J; Fozzatti L; Willingham M; Cheng SY
Endocrinology; 2012 Oct; 153(10):5090-100. PubMed ID: 22919057
[TBL] [Abstract][Full Text] [Related]
12. A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant.
Kim DW; Park JW; Willingham MC; Cheng SY
Hum Mol Genet; 2014 May; 23(10):2651-64. PubMed ID: 24381310
[TBL] [Abstract][Full Text] [Related]
13. Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer.
Park S; Willingham MC; Qi J; Cheng SY
Endocr Relat Cancer; 2018 Oct; 25(10):865-877. PubMed ID: 29914872
[TBL] [Abstract][Full Text] [Related]
14. Differential recruitment of nuclear coregulators directs the isoform-dependent action of mutant thyroid hormone receptors.
Fozzatti L; Lu C; Kim DW; Cheng SY
Mol Endocrinol; 2011 Jun; 25(6):908-21. PubMed ID: 21474540
[TBL] [Abstract][Full Text] [Related]
15. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.
Battaglia S; Maguire O; Thorne JL; Hornung LB; Doig CL; Liu S; Sucheston LE; Bianchi A; Khanim FL; Gommersall LM; Coulter HS; Rakha S; Giddings I; O'Neill LP; Cooper CS; McCabe CJ; Bunce CM; Campbell MJ
Carcinogenesis; 2010 Sep; 31(9):1650-60. PubMed ID: 20466759
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.
Park JW; Han CR; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408
[TBL] [Abstract][Full Text] [Related]
17. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
Ying H; Willingham MC; Cheng SY
Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082
[TBL] [Abstract][Full Text] [Related]
18. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
20. Thyroid hormone signaling in vivo requires a balance between coactivators and corepressors.
Vella KR; Ramadoss P; Costa-E-Sousa RH; Astapova I; Ye FD; Holtz KA; Harris JC; Hollenberg AN
Mol Cell Biol; 2014 May; 34(9):1564-75. PubMed ID: 24550004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
